Opus Genetics, Inc.

NASDAQ:IRD

Biotechnology

Healthcare
$3.92 -0.12%

-$0.01 today

Market cap
$326.13M
Beta
0.55
P/E (TTM)
-33.0
EPS (TTM)
-$0.12
52W Low $0.90High $5.81

Volume 0.75M

Average 0.81M

Returns on capital

Opus Genetics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-323.1%

avg -164.4%

ROIC

-90.9%

avg -47.4%

ROA

-98.7%

avg -134.2%

Analysis

ROIC is currently the strongest return metric at -90.9% versus its period average of -47.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

George Magrath

Chief Executive Officer & DirectorUSD 973.79K412.01M2.44%

Ashwath Jayagopal

Chief Scientific & Development OfficerUSD 682.36K43509.23K0.62%

Joseph K. Schachle

Chief Operating OfficerUSD 635.92K61286.67K0.35%

Amy Zaremba Rabourn

Head of Financial Quality AssuranceUSD 434.1K45188.67K0.23%

Bernhard Hoffmann

Senior Vice President of Corporate Development & SecretaryUSD 434.1K7029.50K0.04%

Andrew Murphy

Chief Scientific Officer————

Benjamin R. Yerxa

President & Director—60670.92K0.81%

Chris Ernst

Chief Technology Officer————

Robert E. Gagnon

Chief Financial Officer & Principal Accounting Officer—52542.38K0.66%

Bindu Manne

Head of Market Development & Commercialization————

Jenny Kobin

Investor Relations Officer————

Sally Tucker

Chief Medical Officer & Senior Vice President of Clinical Development————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 3, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$323,693.40

Sells

24

$19.68M

Net Transaction Value

−$19.35M

Net selling

Most Active

Magrath George

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 3, 26

Magrath George

Direct

Sell$110.2K
Oct 23, 26

SCHACHLE JOSEPH K

Direct

Sell$17K
Oct 23, 26

YERXA BENJAMIN R

Direct

Sell$27.2K
Oct 23, 26

YERXA BENJAMIN R

Direct

Sell$90.1K
Oct 23, 26

Gagnon Robert E.

Direct

Sell$49.6K
Oct 23, 26

Magrath George

Direct

Sell$34.4K
Sep 30, 26

Foundation Fighting Blindness Retinal Degeneration Fund

Direct

Sell$2.8M
Sep 3, 26

Gagnon Robert E.

Direct

Sell$127.2K
Jul 23, 26

YERXA BENJAMIN R

Direct

Sell$22.1K
Jul 23, 26

SCHACHLE JOSEPH K

Direct

Sell$13.7K

1–10 of 26

Summary

Insiders reported 2 buys worth $323,693.40 and 24 sells worth $19.68M over the last 12 months. That adds up to net selling of $19.35M. Magrath George was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A-29.1%
+74.4% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at -29.1% over three years. Forward estimates point to Revenue at +74.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Opus Genetics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IRD's management, answered from reported figures.

Who manages IRD?

Opus Genetics, Inc. (IRD) lists 12 active executives. The top listed executive is Andrew Murphy, Chief Scientific Officer.

Are IRD insiders buying or selling?

Recent insider activity shows net selling of $15.21M.